<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704050</url>
  </required_header>
  <id_info>
    <org_study_id>2830294</org_study_id>
    <nct_id>NCT04704050</nct_id>
  </id_info>
  <brief_title>Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence</brief_title>
  <acronym>EDORA</acronym>
  <official_title>Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence Post Ablation: The EDORA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marrek, INC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiac Designs Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Preventice</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have undergone cardiac ablation will be randomized and blinded to one of two&#xD;
      groups; one group will receive dronedarone while the other group will receive a placebo. The&#xD;
      incidence of atrial fibrillation recurrence, as well as atrial fibrosis progression, will be&#xD;
      analyzed between the two trial groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to determine whether dronedarone is effective in slowing the&#xD;
      progression of fibrosis and decreasing atrial fibrillation recurrence in patients who have&#xD;
      undergone ablation therapy.&#xD;
&#xD;
      Patients with atrial fibrillation (AF) undergoing ablation will be stratified by age and&#xD;
      gender (&gt;65 years and &lt;65 years, male and female) as well as by type of atrial fibrillation&#xD;
      (paroxysmal, persistent, etc.) and then randomized to one of two trial groups. They will&#xD;
      either receive dronedarone 400 mg BID (twice daily) (treatment group) or placebo (control&#xD;
      group). The control group will be started on placebo, and treating physicians will be advised&#xD;
      to limit the initiation of anti-arrhythmic drugs (standard of care, SOC) to necessary cases&#xD;
      only, avoiding amiodarone and dronedarone.&#xD;
&#xD;
      Each patient will receive a pre-ablation Cardiac Magnetic Resonance imaging (CMR) (SOC) scan,&#xD;
      followed by scans at 3 and 12-month post-ablation. Quality of Life (QoL) changes will be&#xD;
      evaluated from baseline and at 3 months and 12-months via the Atrial Fibrillation Effect on&#xD;
      Quality-Of-Life (AFEQT) online questionnaire form. AF burden (frequency, duration and&#xD;
      severity of an AF episode) if present, will be evaluated from baseline and at 3 months and&#xD;
      12-months via the Atrial Fibrillation Severity Scale (AFSS) online questionnaire form.&#xD;
&#xD;
      Patients will be followed post-ablation for AF recurrence and burden assessment with a daily&#xD;
      electrocardiogram (ECG) Check device and will receive continuous ECG monitoring via a 30-day&#xD;
      ECG wearable patch starting at discharge (SOC), then at 3,6,9 and 12 months post-ablation.&#xD;
&#xD;
      Phone call visits will occur at 6 and 9 months to monitor for medication compliance as well&#xD;
      as to assess that devices are working accordingly. Evaluation of adverse events (AE's) as&#xD;
      well as whether a patient has reached any trial endpoints will be analyzed at this time.&#xD;
&#xD;
      Physicians will be advised to avoid adjustments in drug therapy unless necessary (severely&#xD;
      symptomatic patients, patients with heart failure). Severely symptomatic patients will be&#xD;
      defined as, patients with non-tolerated palpitations or chest pain, dizziness, syncope,&#xD;
      dyspnea, or suddenly reduced ability to exercise.&#xD;
&#xD;
      Any initiation or change of an anti-arrhythmic treatment in the treatment or control group&#xD;
      will be considered as a secondary endpoint. Patients will continue to be monitored for&#xD;
      fibrosis progression and AF burden via CMR scans and ECG wearable devices until the end of&#xD;
      the follow-up period. In the case of AF recurrence after ablation, anti-arrhythmic drugs&#xD;
      (AAD) initiation or change will be left to the discretion of the treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-ablation Atrial Fibrillation Recurrence</measure>
    <time_frame>Up to 56 weeks. From date of ablation until the date of first documented Atrial Fibrillation recurrence, whichever came first, assessed up to 56 weeks.</time_frame>
    <description>Time to first atrial fibrillation recurrence after ablation in both treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-ablation Atrial Fibrillation Recurrence</measure>
    <time_frame>Through trial completion, an average of 1 year.</time_frame>
    <description>New anti-arrythmic drug (AAD) initiation for atrial fibrillation recurrence after ablation in both treatment groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression of Atrial Fibrosis</measure>
    <time_frame>Comparing baseline CMR scan to 12 month CMR scan.</time_frame>
    <description>To see whether patients in the treatment group have change in atrial fibrosis, visualized on their CMR scans compared to those who were in the placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antiarrhythmic Initiation or change</measure>
    <time_frame>Up to 56 weeks. From the date of ablation until the date of first documented Antiarrhythmic drug initiation/change, whichever came first, assessed up to 56 weeks.</time_frame>
    <description>Any initiation or change to anti-arrhythmic therapy after ablation to either the treatment or control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Episodes</measure>
    <time_frame>1 year</time_frame>
    <description>Incidences or symptoms of atrial fibrillation (e.g. palpitations, chest pain, dyspnea, dizziness, syncope, unusual fatigue and weakness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repeat Cardiac Ablation</measure>
    <time_frame>1 year</time_frame>
    <description>Whether patients in either treatment arm require a repeat cardiac ablation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardioversion</measure>
    <time_frame>1 year</time_frame>
    <description>Whether patients in either treatment arm require cardioversion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Burden</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of time a patient is in atrial fibrillation during the monitoring period, 24-48 hours and, at 3 months and 12 months post-ablation. Burden will be recorded as a time-weighted average (%) based on data from wearable devices.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Online questionnaire form)</measure>
    <time_frame>1 year</time_frame>
    <description>This will be assessed through the Atrial Fibrillation Effect on Quality-Of-Life (AFEQT) online questionnaire form at baseline, 3 and 12 month follow up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Through trial completion, up to 56 weeks.</time_frame>
    <description>Assessment of adverse events related to dronedarone. Evaluated at 3, 12 months visits and during 6 &amp; 9 month phone call visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF Burden (Online questionnaire form)</measure>
    <time_frame>1 year</time_frame>
    <description>This will be assessed through the Atrial Fibrillation Severity Scale (AFSS) online questionnaire form at baseline, 3 and 12 month follow up visits.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Records of any cardiac events requiring hospitalization.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>Records of mortality associated with cardiovascular events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke/ Transient Ischemic Attacks (TIA)</measure>
    <time_frame>1 year</time_frame>
    <description>Records of stroke or TIA based on cardiac emboli.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation Recurrent</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dronedarone 400 mg orally, twice per day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet orally, twice per day (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dronedarone 400 mg Oral Tablet</intervention_name>
    <description>Dronedarone is an anti-arrhythmic drug with properties belonging to Vaughan-Williams class I-IV.&#xD;
Participants will receive dronedarone 400 mg tablet, to be taken orally and twice daily for 52 weeks.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Multaq®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a placebo tablet matching the physical appearance of dronedarone, to be taken orally and twice daily for 52 weeks.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Patients must meet the following criteria to be enrolled in the trial.&#xD;
&#xD;
          -  Male or female patients aged over 18 years of age.&#xD;
&#xD;
          -  Patients with paroxysmal or persistent atrial fibrillation who are undergoing ablation&#xD;
             of atrial fibrillation, regardless of whether they were receiving an anti-arrhythmic&#xD;
             drug (AADs) before enrollment or not.&#xD;
&#xD;
        Exclusion Criteria: Patients will be excluded from enrollment if any of the following&#xD;
        criteria are present.&#xD;
&#xD;
          -  Any health-related gadolinium/MRI contraindications (e.g. allergy to gadolinium,&#xD;
             pacemakers, Implantable Cardioverter Defibrillators [ICD's], other devices/implants&#xD;
             contraindicated for use of MRI, etc.).&#xD;
&#xD;
          -  Patients weighing &gt;300 Ibs. (MRI quality decreases as BMI increases).&#xD;
&#xD;
          -  Patients with contraindications to dronedarone. (Including patients with decompensated&#xD;
             heart failure or class NYHA IV (New York Heart Association Class IV), second or&#xD;
             third-degree atrioventricular (AV) block or sick-sinus syndrome [except when used in&#xD;
             conjunction with a functioning pacemaker]), concomitant use of strong cytochrome P450,&#xD;
             family 3, subfamily A (CYP-3A) inhibitors or other Class I or III AADs, drug or herbal&#xD;
             products that prolongs the QT interval and may induce Torsades de Pointes.&#xD;
&#xD;
          -  Liver or lung toxicity related to the previous use of amiodarone, severe hepatic&#xD;
             impairment including any stage of cirrhosis and acute liver failure, bradycardia&#xD;
             &lt;50bpm, QTc Bazett interval &gt;500ms or PR interval &gt;280ms, or hypersensitivity to the&#xD;
             active substance or to any of its excipients.&#xD;
&#xD;
          -  Acute or chronic severe renal disease with a low glomerular filtration rate (GFR), &lt;30&#xD;
             mL per minute per 1.73m2 will be excluded from the trial.&#xD;
&#xD;
          -  Patients with a history of prior left atrial ablation or valvular cardiac surgery&#xD;
             (myocardial scarring/fibrosis from prior surgeries may confound data).&#xD;
&#xD;
          -  Pre-menopausal (last menstruation &lt;1 year prior to screening) who:&#xD;
&#xD;
               1. are pregnant or breast-feeding or plan to become pregnant during the study period&#xD;
                  or,&#xD;
&#xD;
               2. are not surgically sterile or,&#xD;
&#xD;
               3. are of childbearing potential and not practising two acceptable methods of birth&#xD;
                  control or,&#xD;
&#xD;
               4. do not plan to continue practising two acceptable methods of birth control&#xD;
                  throughout the trial (highly effective methods of birth control are defined as&#xD;
                  those, used alone, or in combination, that result in a low failure rate i.e. less&#xD;
                  than 1% per year when used consistently and correctly).&#xD;
&#xD;
          -  Patients who do not have access to the Internet/e-mail.&#xD;
&#xD;
          -  Patients without daily access to a smart phone-compatible with ECG Check device&#xD;
             application and ability to upload ECG tracings for the entire follow-up period.&#xD;
&#xD;
          -  Patients unable or unwilling to return to the clinic for follow up CMR scans.&#xD;
&#xD;
          -  Patients with cognitive impairments who are unable to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Participant eligibility is based on the self-representation of gender identity.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nassir F Marrouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agnieszka Jezierska-Drutel (Study Coordinator), PhD</last_name>
    <phone>5049886443</phone>
    <email>ajezierskadrutel@tulane.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arezu Bhatnagar (Medical Monitor), MD MSCRM BSc</last_name>
    <phone>5049886203</phone>
    <email>abhatnagar@tulane.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Jezierska-Drutel, PhD</last_name>
      <phone>504-988-6443</phone>
      <email>ajezierskadrutel@tulane.edu</email>
    </contact>
    <contact_backup>
      <last_name>Arezu Bhatnagar, MD MSCRM BSc</last_name>
      <phone>504-988-6203</phone>
      <email>abhatnagar@tulane.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nassir F Marrouche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma JH, Crijns HJ, Van Gelder IC; RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004 Jan 21;43(2):241-7.</citation>
    <PMID>14736444</PMID>
  </reference>
  <reference>
    <citation>Blomström-Lundqvist C, Gizurarson S, Schwieler J, Jensen SM, Bergfeldt L, Kennebäck G, Rubulis A, Malmborg H, Raatikainen P, Lönnerholm S, Höglund N, Mörtsell D. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. JAMA. 2019 Mar 19;321(11):1059-1068. doi: 10.1001/jama.2019.0335.</citation>
    <PMID>30874754</PMID>
  </reference>
  <reference>
    <citation>Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 Feb 1;378(5):417-427. doi: 10.1056/NEJMoa1707855.</citation>
    <PMID>29385358</PMID>
  </reference>
  <reference>
    <citation>Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693.</citation>
    <PMID>30874766</PMID>
  </reference>
  <reference>
    <citation>Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014 Feb 5;311(5):498-506. doi: 10.1001/jama.2014.3. Erratum in: JAMA. 2014 Nov 5;312(17):1805.</citation>
    <PMID>24496537</PMID>
  </reference>
  <reference>
    <citation>Kheirkhahan M, Baher A, Goldooz M, Kholmovski EG, Morris AK, Csecs I, Chelu MG, Wilson BD, Marrouche NF. Left atrial fibrosis progression detected by LGE-MRI after ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2020 Apr;43(4):402-411. doi: 10.1111/pace.13866.</citation>
    <PMID>31867751</PMID>
  </reference>
  <reference>
    <citation>Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78. doi: 10.1056/NEJMoa0803778. Erratum in: N Engl J Med. 2009 Jun 4;360(23):2487. N Engl J Med. 2011 Apr 14;364(15):1481.</citation>
    <PMID>19213680</PMID>
  </reference>
  <reference>
    <citation>Akoum N, Fernandez G, Wilson B, Mcgann C, Kholmovski E, Marrouche N. Association of atrial fibrosis quantified using LGE-MRI with atrial appendage thrombus and spontaneous contrast on transesophageal echocardiography in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2013 Oct;24(10):1104-9. doi: 10.1111/jce.12199. Epub 2013 Jul 11.</citation>
    <PMID>23844972</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Atrial Fibrillation Recurrent</keyword>
  <keyword>Heart Murmur</keyword>
  <keyword>Dronedarone</keyword>
  <keyword>Atrial Fibrosis</keyword>
  <keyword>Atrial Fibrosis Progression</keyword>
  <keyword>Atrial Fibrosis Regression</keyword>
  <keyword>Atrial Arrhythmia</keyword>
  <keyword>Cardiac Arrhythmia</keyword>
  <keyword>Cardiovascular Events</keyword>
  <keyword>Multaq</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dronedarone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

